文献速递围术期管理与 ERAS

黑色素瘤前哨淋巴结阳性风险预测工具的准确性比较

Sentinel lymph node positivity in melanoma: Which risk prediction tool is most accurate?
PubMed 文献 · Surgery · 2024-07-11

该多中心研究纳入2018年9月至2022年12月接受前哨淋巴结活检的532例黑色素瘤患者,其中98例(18.4%)前哨淋巴结阳性。整体人群中MSKCC与MIA两种列线图预测准确性相当,但MSKCC工具在≥75岁患者中更优,MIA工具在高核分裂指数患者中更优,两者在≤30岁年轻患者中预测均较差。

要点

  • 整体人群中MSKCC与MIA列线图预测前哨淋巴结阳性准确性相当(AUC 0.693 vs 0.699)。
  • ≥75岁患者MSKCC工具更优(AUC 0.801 vs 0.712,P<.01)。
  • 核分裂指数≥2/mm²患者MIA工具更优(AUC 0.717 vs 0.659,P=.027)。

核心结论

  • MSKCC与MIA两种风险预测工具在特定人群中预测前哨淋巴结阳性的能力存在差异。
  • MSKCC工具对老年患者预测更佳,MIA工具在高核分裂指数患者中更准确。
  • 两种列线图在年轻患者中预测前哨淋巴结阳性表现均较差。

研究设计与样本

  • 多中心研究,纳入2018年9月至2022年12月接受前哨淋巴结活检的黑色素瘤患者。
  • 共532例患者接受前哨淋巴结活检,其中98例(18.4%)前哨淋巴结阳性。
  • 采用受试者工作特征曲线及曲线下面积分析两种风险预测工具的准确性。

主要发现

  • 年龄增长与前哨淋巴结阳性率呈负相关(P<.01)。
  • ≤30岁患者前哨淋巴结阳性率为35.7%,≥75岁患者为9.7%。
  • 整体人群中MSKCC工具AUC为0.693,MIA工具AUC为0.699。
  • ≥75岁患者中MSKCC工具AUC为0.801,MIA工具AUC为0.712(P<.01)。
  • 核分裂指数≥2/mm²患者中MSKCC工具AUC为0.659,MIA工具AUC为0.717(P=.027)。

临床怎么用

  • 选择前哨淋巴结活检风险预测工具时可结合患者年龄与核分裂指数个体化选用。
  • 老年患者可优先考虑MSKCC列线图,高核分裂指数患者可优先考虑MIA列线图。
  • 年轻患者使用现有列线图预测价值有限,需谨慎解读其评估结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sentinel lymph node biopsy for melanoma determines treatment and prognostic factors and improves disease-specific survival. To risk-stratify patients for sentinel lymph node biopsy consideration, Memorial Sloan Kettering Cancer Center and Melanoma Institute Australia developed nomograms to predict sentinel lymph node positivity. We aimed to compare the accuracy of these 2 nomograms. METHODS: A multi-institutional study of patients with melanoma receiving sentinel lymph node biopsy between September 2018 and December 2022 was performed. The accuracy of the 2 risk prediction tools in determining a positive sentinel lymph node biopsy was analyzed using receiver operating characteristic curves and area under the curve. RESULTS: In total, 532 patients underwent sentinel lymph node biopsy for melanoma; 98 (18.4%) had positive sentinel lymph node. Increasing age was inversely related to sentinel lymph node positivity (P < .01); 35.7% of patients ≤30 years had positive sentinel lymph node compared with 9.7% of patients ≥75 years. When we analyzed the entire study population, accuracy of the 2 risk prediction tools was equal (area under the curveMemorial Sloan Kettering Cancer Center: 0.693; area under the curveMIA: 0.699). However, Memorial Sloan Kettering Cancer Center tool was a better predictor in patients aged ≥75 years (area under the curveMemorial Sloan Kettering Cancer Center: 0.801; area under the curveMelanoma Institute Australia: 0.712, P < .01) but Melanoma Institute Australia tool performed better in patients with a higher mitotic index (mitoses/mm2 ≥2; area under the curveMemorial Sloan Kettering Cancer Center: 0.659; area under the curveMelanoma Institute Australia: 0.717, P = .027). Both models were poor predictors of sentinel lymph node positivity in young patients (age ≤30 years; area under the curveMemorial Sloan Kettering Cancer Center: 0.456; area under the curveMelanoma Institute Australia: 0.589, P = .283). CONCLUSION: The current study suggests that the 2 risk stratification tools differ in their abilities to predict sentinel lymph node positivity in specific populations: Memorial Sloan Kettering Cancer Center tool is a better predictor for older patients, whereas Melanoma Institute Australia tool is more accurate in patients with a higher mitotic index. Both nomograms performed poorly in predicting sentinel lymph node positivity in young patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Ragsdale M, Dow B, Fernandes D, et al. Sentinel lymph node positivity in melanoma: Which risk prediction tool is most accurate? Surgery. 2024. PMID: 38997863. doi:10.1016/j.surg.2024.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。